Seeking Alpha This study, unlike the first trial, is going to look at the combination of rituximab, which with PIXUVRI, compared to rituximab and gemcitabine or GEM-R as it's called in Europe, is a frequently used double therapy. And this study will look at second ... and more »
FiercePharma NICE recently rejected Avastin in combination with gemcitabine and carboplatin to treat recurrent, advanced ovarian cancer. Earlier this year, the agency turned down Avastin for metastasized ovarian cancer in combination with paclitaxel and carboplatin.
pharmabiz.com The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri -rituximab to gemcitabine -rituximab in patients who have ... and more »
OncLive The comparator arm included an investigator's choice of bendamustine plus rituximab or gemcitabine plus rituximab. The preliminary efficacy of the combination ...
Profitable.com (press release) The use of IV-administered vitamin C in combination with cytotoxic chemotherapy is further encouraged by a recent report showing that vitamin C potentiated the antitumor activity of gemcitabine against seven human and one murine pancreatic cancer cell ... and more »
Food Consumer The investigators also conducted other research showing that vitamin C can be used to potentiate the antitumor activity of chemotherapy like gemcitabine against seven human and one murine pancreatic cancer in vitro. This is important because two lines ...
PharmaTimes It is also refusing NHS funding for use with carboplatin and Lilly's Gemzar ( gemcitabine ) to treat the first recurrence of advanced ovarian cancer if it ha...
Healio Maintenance therapy with paclitaxel and gemcitabine improved PFS and OS in women with metastatic breast cancer who initially exhibited disease control after first-line treatment with six cycles of the same combination, according to results of a phase 3 ...
PR Newswire (press release) However, studies conducted with orally dosed supplements did not demonstrate any clinical benefit in cancer patients, most likely due to the finding that the levels of orally-administered vitamin C delivered to a patient's blood stream were ... and more »
Insider Monkey (blog) A phase 1 study of the biologic in combination with gemcitabine showed an overall response rate of 42%. The company also said the treatment was generally well tolerated. It's still too early in the development cycle to predict how effective PEGPH20 ... and more »
